Amino acid changes present after triple therapy with TEL and BOC in 21 patients without SVR.

*Letter on the left represents the wild type amino acid (aa), on the right, the aa substitution. Amino acid changes known to confer resistance to PI's are reported in bold and other observed sequence variants are shown in italics.**Clonal analysis revealed 1 clone with the resistance mutation V55A.+Only found as a minor quasispecies pre-treatment.++I170V has been described as a polymorphism not associated with resistance in GT3.GT; genotype, BT; Breakthrough. NR; Non-response. RL; Relapse.Amino acid changes present after triple therapy with TEL and BOC in 21 patients without SVR.* 左侧字母代表野生型氨基酸（amino acid，aa），右侧字母代表该氨基酸的替换变异。已知可赋予蛋白酶抑制剂（Protease Inhibitor，PI）耐药性的氨基酸改变以粗体标注，其余观测到的序列变异以斜体展示。 ** 克隆分析显示存在1个携带耐药突变V55A的克隆。 + 仅在治疗前以次要准种形式被检出。 ++ I170V被描述为基因型3（GT3）中与耐药性无关的多态性。 GT；基因型（genotype），BT；治疗突破（Breakthrough），NR；无应答（Non-response），RL；复发（Relapse）。 本数据集收录了21例未获得持续病毒学应答（Sustained Virological Response，SVR）的患者，在接受替拉瑞韦（Telaprevir，TEL）与博赛泼维（Boceprevir，BOC）三联治疗后出现的氨基酸改变。